A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 24 Sep 2015 Results published in the Journal of Clinical Hypertension (Greenwich).
- 28 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.